Find any stock by ticker or company name
Barcha huquqlar himoyalangan.
0.00
0.00 (0.00%)
Aimwell Partners Inc. (OTCID:AIMN) invites anyone to check the work at aimwellbio.com/atlas , confirms multiple physicians and prospective collaboration partners in active discussions following the Trustr acquisition, and publishes the single address where serious parties can reach the company directly. MIAMI, FL / ACCESS Newswire / September 2, 2026 / Aimwell Partners Inc. (OTCID:AIMN), the company behind AimwellBio, the gated professional healthcare intelligence network, today did something most companies in this market will not do.
Definitive agreement executed with inventor Dr. Christopher A. Jones; contributors and strategic advisors from the platform's development history to be announced individually as their agreements are signed MIAMI, FL / ACCESS Newswire / August 27, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced that its subsidiary, Aimwell Bio, Inc., has executed the definitive Intellectual Property Purchase and Assignment Agreement completing its acquisition of the Trustr behavioral engagement portfolio from its principal inventor, Dr. Christopher A.
Executed IP assignment brings a decade of technology, published research, and pharma-tested behavioral engagement capabilities into AimwellBio as the Company expands its scientific and medical advisory network MIAMI, FL / ACCESS Newswire / August 17, 2026 / AimwellBio (OTCID:AIMN) today announced the executed assignment of the Trustr intellectual property portfolio, a patented behavioral engagement system designed to measure real-world patient behavior and use precisely timed, data-driven interventions and rewards to support sustained adherence. The technology brings a substantial development history to the AimwellBio platform.
Behavioral engagement technology carries documented institutional lineage spanning Oxford, the University of Vermont, Cornell, AMCP, and a Sanofi pilot program, as inventor Dr. Chris A. Jones joins AimwellBio's Board of Advisors and leads further expansion.
MIAMI, FL / ACCESS Newswire / August 6, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced that it has reached an agreement in principle to acquire a portfolio of intellectual property valued at approximately $10 million. The proposed transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by all parties, and review by their respective legal counsel.
There is no data to display
